Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06200103 · ClinicalTrials.gov registry record · Phase 2

Schedule De-Escalation of 177Lu-PSMA-617 for the Treatment of Metastatic Castrate Resistant Prostate Cancer

A Phase 2 study of Stage IVB Prostate Cancer AJCC v8 and Castration-Resistant Prostate Carcinoma, sponsored by Mayo Clinic.

Recruiting
Registry status
Phase 2
Development phase
236
Enrollment target
1
Study location

NCT06200103: Recruiting Phase 2 study of Stage IVB Prostate Cancer AJCC v8 and Castration-Resistant Prostate Carcinoma, sponsored by Mayo Clinic.

NCT06200103 is a Phase 2 study of Stage IVB Prostate Cancer AJCC v8 and Castration-Resistant Prostate Carcinoma that is actively recruiting participants, run by Mayo Clinic. The registered enrollment target is 236 participants, above the 172-participant average among 45 other Stage IVB Prostate Cancer AJCC v8 trials with a reported enrollment target (37% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06200103, a Phase 2 study of Stage IVB Prostate Cancer AJCC v8 and Castration-Resistant Prostate Carcinoma, is actively recruiting participants, sponsored by Mayo Clinic.

RECRUITING
Registry status
Phase 2
Development phase
236 participants
Enrollment target
1
Study location

Study Summary

This phase II trial studies how to improve the usage of Lu 177 vipivotide tetraxetan (177Lu-prostate-specific membrane antigen \[PSMA\]-617) for treating patients with castration-resistant prostate cancer that has spread from where it first started (primary site), to other places in the body (metastatic) utilizing a treatment pause after 5 cycles of therapy versus standard continuous treatment for 6 cycles. Lutetium is a radioligand therapy (RLT). RLT uses a small molecule (in this case 177Lu-PSMA-617) that carries a radioactive component to destroy tumor cells. When lutetium is injected into the body, it attaches to the PSMA receptor found on tumor cells. After lutetium attaches to the PSMA receptor, its radiation component destroys the tumor cell. Giving 177Lu-PSMA-617 for 5 cycles versus 6 cycles may better treat patients with metastatic castrate resistant prostate cancer.

Conditions Studied

Stage IVB Prostate Cancer AJCC v8 Castration-Resistant Prostate Carcinoma

Interventions

  • PROCEDURE Biospecimen Collection
  • PROCEDURE Computed Tomography
  • PROCEDURE Bone Scan
  • OTHER Clinical Observation
  • OTHER Gallium Ga 68 Gozetotide

Study Locations (1)

Minnesota

  • Mayo Clinic in Rochester - Rochester

Trial Details

FieldValue
Enrollment Target 236 participants
Start Date 2024-05-03
Est. Completion 2029-12-31
Phase Phase 2
Mayo Clinic

2,844 total trials

What NCT06200103 shows while recruiting

NCT06200103 is an interventional study that assigns participants to a tested intervention. The registered 236 participants enrollment target is mid-sized for trials with a published cap, above the 172-participant average among 45 other Stage IVB Prostate Cancer AJCC v8 trials with a reported enrollment target (37% higher).

The record links to 2 conditions, with Stage IVB Prostate Cancer AJCC v8 appearing as the primary indexed condition, and to 5 interventions - of which Biospecimen Collection is the first listed.

NCT06200103 reports a single indexed study location in Minnesota.

Frequently Asked Questions

What is clinical trial NCT06200103 about?

NCT06200103 is a clinical study titled "Schedule De-Escalation of 177Lu-PSMA-617 for the Treatment of Metastatic Castrate Resistant Prostate Cancer". This phase II trial studies how to improve the usage of Lu 177 vipivotide tetraxetan (177Lu-prostate-specific membrane antigen \[PSMA\]-617) for treating patients with castration-resistant prostate cancer that has spread from where it first started (primary site), to other places in the body (metast...

What is the current status of trial NCT06200103?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 236 participants. The study started on 2024-05-03. Estimated completion is 2029-12-31.

What conditions does trial NCT06200103 study?

This clinical trial studies the following conditions: Stage IVB Prostate Cancer AJCC v8, Castration-Resistant Prostate Carcinoma.

What interventions are being tested in trial NCT06200103?

The interventions under investigation include: Biospecimen Collection (PROCEDURE), Computed Tomography (PROCEDURE), Bone Scan (PROCEDURE), Clinical Observation (OTHER), Gallium Ga 68 Gozetotide (OTHER).

Who is sponsoring clinical trial NCT06200103?

This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06200103 being conducted?

This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Stage IVB Prostate Cancer AJCC v8

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06200103's enrollment target sits among peer trials

236 7th of 45 higher than 39 of 45 other Stage IVB Prostate Cancer AJCC v8 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Stage IVB Prostate Cancer AJCC v8 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT04995341 · 236 participants · NA

    Retinal Microanatomy in Retinopathy of Prematurity (BabySTEPS2)

  • NCT05822362 · 236 participants · Phase 2

    CBD for Individuals at Risk for Alzheimer's Disease

  • NCT06494072 · 236 participants · Phase 4

    Short Versus Standard of Care Antibiotic Duration for Children Hospitalized for CAP

  • NCT06615557 · 236 participants · Phase 3

    Fasedienol Nasal Spray for the Acute Treatment of Anxiety in Adults With Social Anxiety Disorder (PALISADE-4)

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

More recruiting context for NCT06200103

Source: ClinicalTrials.gov NCT06200103, the US trial registry maintained by the National Library of Medicine. NCT06200103 (mid enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.